NEW YORK, Sept 13 (Reuters) - The public has good reason to look beyond Pfizer Inc’s (PFE.N) disappointing track record in developing new medicines, the drugmaker’s research chief told investors on Monday.
NEW YORK, Sept 13 (Reuters) - The public has good reason to look beyond Pfizer Inc’s (PFE.N) disappointing track record in developing new medicines, the drugmaker’s research chief told investors on Monday.
